The UK ATMP clinical trials database is developed and published by CGT Catapult. The database aims to assess the progress and state of play of the UK ATMP clinical development landscape. The database is updated annually and provides, what we believe to be, a comprehensive and accurate review of the UK ATMP clinical trial landscape.
An annual commentary is published alongside the UK ATMP clinical trials database, highlighting key themes and developments that have emerged throughout the year. The commentary also includes details of any key changes to the methodology by which data collection or analysis is undertaken.
How we collect the data
The database is compiled and verified by the CGT Catapult team, and includes:
- all ATMP trials, including non-interventional long-term follow-up (LTFU) trials
- academic and commercial trials
- ongoing trials in the UK, regardless of the nationality of the sponsor
To generate our data, we used consistent and systematic methods to interrogate and refine automatically generated data using the comprehensive GlobalData Database. It is important to note that CGT Catapult data may differ from other databases which often include cell therapies which do not fulfil the criteria for ATMPs or may include the same trial in more than one category.
The input of the cell and gene therapy community is important however to help us maintain its relevance, and we welcome updates, additions and corrections, which can be sent to us here.